Project Grant R01CA300198
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $637,509 to the University of California, San Diego on May 11, 2026, under the Cancer Biology Research program (CFDA 93.396). This five-year research initiative, concluding April 30, 2031, focuses on elucidating the molecular mechanisms of cancer cell signaling autonomy through investigation of GIV (GA-Interacting Vesicle-Associated Protein) as a master regulator. The research deliverables...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded University of California, San Diego a $410,115 project grant under the Cancer Biology Research program (CFDA 93.396) beginning August 1, 2025, with completion scheduled for July 31, 2027. This research initiative develops improved preclinical models for pancreatic ductal adenocarcinoma (PDAC) by incorporating three-dimensional high-density type I collagen into tumor modeling systems. The project addresses a...
- Federal Project Grant Award Summary The National Cancer Institute awarded $661,721 to the University of California, San Diego under the Cancer Biology Research program (CFDA 93.396) on April 1, 2026, for a five-year project extending through March 31, 2031. The award supports systematic functional mapping and mechanistic interrogation of intrinsically disordered regions (IDRs) in oncogenic proteins that drive cancer development and progression. The research will employ high-throughput functional...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded UC San Diego a $771,811 Project Grant effective June 1, 2026, through May 31, 2029, under the Cancer Treatment Research program (CFDA 93.395). This award supports research aimed at identifying small molecule activators of Type I Interferon signaling to enhance cancer treatment efficacy. The project addresses a critical gap in immunotherapy by developing inhibitors targeting USP18, a ubiquitin protease that suppresses...
- Federal Project Grant Award Summary The University of California, Davis received a $149,394 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research program (CFDA 93.394) effective August 1, 2025 through July 31, 2030. This award supports research in targeted radiotheranostics—the development and clinical translation of diagnostic and therapeutic radiopharmaceuticals that enable integrated imaging and treatment of cancer. The research encompasses the...
- Federal Grant Award Summary The National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), awarded the University of California, San Diego a Project Grant of $694,643 on May 7, 2026, with an ultimate completion date of April 30, 2031. This award supports research targeting the Hippo-YAP/TEAD signaling network in head and neck squamous cell carcinoma (HNSCC), with the objective of developing improved treatment approaches for this disease. The research addresses...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $144,981 Project Grant to the University of California, San Diego on September 3, 2025, under the Cancer Research Manpower program (CFDA 93.398). The grant funds a two-year research project through August 31, 2027, investigating the role of extrachromosomal DNA (ecDNA) in glioblastoma multiforme (GBM) heterogeneity and plasticity. The research deliverables include characterization of how ecDNA shapes the...
- Federal Grant Award Summary The National Cancer Institute awarded a $411,206 Project Grant to the University of California, San Diego under the Cancer Treatment Research program (CFDA 93.395) on May 14, 2026, with a completion date of April 30, 2028. This award supports the development of small molecule inhibitors targeting the proton-sensing receptor GPR68 for pancreatic ductal adenocarcinoma (PDAC) therapy. The research addresses a critical clinical need, as PDAC accounts for approximately 90%...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the University of California, Berkeley a $712,375 Project Grant under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) effective April 1, 2026, with completion scheduled for March 31, 2031. The project focuses on developing the ADAPT PRO System, a single, universal, and digitally programmable radiofrequency (RF) system that enables magnetic resonance imaging (MRI) of any nucleus beyond the standard...
- Federal Grant Award Summary The University of California, Santa Barbara received a $402,400 Project Grant from the National Cancer Institute under the Cancer Biology Research program (CFDA 93.396) effective September 1, 2025, through August 31, 2027. This award supports fundamental research investigating the structure-function relationship of the Wnt destruction complex (DC), a protein machine comprising disordered scaffold proteins APC and AXIN that regulate critical signaling interactions in...
The University of California, San Diego received a $486,094 Project Grant award from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) for research addressing weak cell adhesion as a prognostic signature of invasive breast cancer. The grant, awarded June 19, 2026, with completion targeted for May 31, 2031, supports fundamental and translational research to establish the role of weak adhesion in cancer initiation, metastasis, and patient outcomes. The research leverages newly patented adhesion technology and model systems to investigate how cancer cells with weaker cell-to-cell adhesion migrate faster and metastasize more frequently compared to strongly adherent cells, with particular focus on distinguishing high-risk ductal carcinoma in situ (DCIS) cases that may progress to metastatic disease despite standard treatment. The project addresses a significant clinical unmet need, as early-detected low-grade breast cancers such as DCIS relapse in up to 20 percent of cases, affecting over 12,000 U.S. women annually. The research will evaluate the tumor-initiating potential of weakly versus strongly adherent tumor cells using murine breast cancer models and human tumor samples to develop improved diagnostic and prognostic technologies that can better identify patients at risk for disease progression and distinguish cancer cells from non-cancer cells in surrounding tissue.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $486.1k | 6/19/26 |